Observational Prospective Study on Patients With Symptomatic Uterine Fibroids Treated With VizAblate® Intrauterine-ultrasound Guided RF Ablation

NCT ID: NCT01998854

Last Updated: 2015-03-11

Basic Information

• Recruitment Status: TERMINATED
• Total Enrollment: 4 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2013-02-28
• Study Completion Date: 2015-01-31

Brief Summary

Study is intended to evaluate the one-year safety and clinical status of patients treated for symptomatic uterine fibroids with the VizAblate Intrauterine-ultrasound guided radio frequency (RF) ablation system. Particular attention will be directed to recording safety outcomes including incidence of uterine cavity synechiae. In addition, information on quality of life will be collected.

Overall study duration (first patient enrolled through last patient exit) will be comprised of approximately 12 months of patient enrollment up to 1 month for scheduling of treatment, and 12 months of follow-up, for a total duration of up to 25 months. Study duration for an individual patient, once enrolled, will be approximately 1 month for baseline observations and treatment scheduling, and 12 months for follow up after treatment for a total duration of approximately 13 months.

Detailed Description

In this single-arm study, subjects who receive transcervical intrauterine-ultrasound guided RF ablation of symptomatic uterine fibroids with the VizAblate® System will be assessed with 3D pelvic sonography with contrast, hysteroscopy, and quality of life questionnaires.

Overall study duration (first patient enrolled through last patient exit) will be comprised of approximately 12 months of patient enrollment up to 1 month for scheduling of treatment, and 12 months of follow-up, for a total duration of up to 25 months. Study duration for an individual patient, once enrolled, will be approximately 1 month for baseline observations and treatment scheduling, and 12 months for follow up after treatment for a total duration of approximately 13 months.

Conditions

Menorrhagia; Leiomyoma; Uterine Fibroids; Uterine Fibroma; Uterine Neoplasms

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

VizAblate treatment

VizAblate System with subject serving as her own control

VizAblate System

Intervention Type: DEVICE

The VizAblate System is indicated for use in transcervical intrauterine-guided radio frequency ablation of uterine fibroids

Interventions

VizAblate System

The VizAblate System is indicated for use in transcervical intrauterine-guided radio frequency ablation of uterine fibroids

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• 28 years of age or older
• Indication for transcervical treatment of uterine fibroids associated with menorrhagia
• Willingness to participate in the study, to attend all follow-up visits and undergo all study assessments, and to sign the informed consent form
• Presence of submucosal and/or intramural fibroids

Exclusion Criteria

• Pregnancy
• ≥40 years of age with desire for current or future fertility, unless the estimated risk/benefit ratio has been determined to be more favorable to future pregnancy than standard therapy
• Non-sterilized patients < 40 years of age, unless the estimated risk/benefit ratio has been determined to be more favorable to future pregnancy than standard therapy
• Active pelvic infection, known or suspected gynecologic malignancy or premalignant condition
• Presence of tubal implant for sterilization
• Previous pelvic irradiation
• Endometrial cavity length, including endocervical canal, < 4.5 cm
• Any abnormality of the vagina or uterine cavity that, in the judgment of the investigator obstructs access of the VizAblate handpiece to the endometrial cavity
• Presence of cardiac pacemaker or other active implant
• Post-menopausal

• Minimum Eligible Age: 28 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Gynesonics

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

David Toub, MD

Role: STUDY_DIRECTOR

Gynesonics

Locations

Le Centre Hospitalier Regional et Universitaire de Tours - Hôpital Bretonneau

Tours, Cedex, France

Assistance Publique Hôpitaux de Paris - Hôpital Bicêtre

Paris, , France

Countries

France

Other Identifiers

CL03537

Identifier Type: -

Identifier Source: org_study_id